

Page 10, line 21, delete "chromosomes" and insert --chromosome--;

Page 11, line 25, delete "E coli" and insert --E. coli--;

Page 12, line 1, delete "E coli" and insert --E. coli--;

Page 13, line 29, delete "threonine" and insert --threonine and--;

Page 15, line 27, delete "devise" and insert --device--;

Page 21, line 20, delete "which confer" and insert --which confers--;

Page 21, line 29, delete "55:121-131).." and insert --55:121-131).--;

Page 23, line 22, delete "sequence" and insert --sequences--;

Page 24, line 9, delete "Merrifield" and insert --(Merrifield--;

Page 34, line 19, delete "formation" and insert --formation.--;

Page 34, line 21, delete "photometric," and insert --photometric--;

Page 37, line 27, delete "techniques.," and insert --techniques.--;

Page 38, line 7, delete "disease ," and insert --disease,--; and

Page 38, line 14, delete "as mouse" and insert --as a mouse--.

IN THE CLAIMS

11. (Amended) A pharmaceutical composition comprising a substantially purified guanosine monophosphate reductase having the amino acid sequence of [claim 1] SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier. *or an enzymatically active fragment thereof*

12. (Amended) A purified antibody which binds specifically to the polypeptide of [claim 1] amino acid sequence of SEQ ID NO:1.

13. (Amended) A purified agonist which specifically binds to and modulates the activity of the [polypeptide of claim 1] amino acid sequence of SEQ ID NO:1.

14. (Amended) A purified antagonist which specifically binds to and modulates the

31162000

B-1
CONT'D.